rethinkPeptides Search
Menu
Study breakdown

How Adrenomedullin Drives the Shift From Compensated to Decompensated Septic Shock

ReviewModerate evidence
The takeaway

Adrenomedullin plays a central role in both the early beneficial vasodilation and the late dangerous cardiovascular collapse of sepsis, making it both a therapeutic target and a biomarker for sepsis progression.

Dual-phase role

ADM helps in early sepsis but kills in late sepsis — the same peptide goes from friend to foe as clearance fails and accumulation grows

What the researchers found

Adrenomedullin contributes to both phases of sepsis: beneficial vasodilation during early compensation and harmful cardiovascular collapse during late decompensation, driven by progressive ADM accumulation from reduced clearance and increased tissue production.

Why it matters

Understanding the dual role of ADM in sepsis — helpful early, harmful late — could guide timing of potential ADM-modulating therapies to preserve early benefits while preventing late collapse.

How the study worked

Review synthesizing data on adrenomedullin dynamics during experimental sepsis, covering tissue production, pulmonary clearance, receptor regulation, and hemodynamic effects across both sepsis phases.

What this study cannot tell us

Review based largely on animal sepsis models. The exact tipping point where ADM shifts from beneficial to harmful is not precisely defined.

How to read the evidence

Moderate evidence from a review integrating multiple experimental sepsis studies with coherent mechanistic framework.

When this study was published

Published in 2001. ADM-targeting therapies (adrecizumab) are now in clinical trials for sepsis, and MR-proADM is a clinical sepsis biomarker.

The bigger picture

Sepsis kills more people than many cancers. Understanding which peptide changes drive the transition from compensated to decompensated shock could enable therapies that prevent this deadly transition.

Questions still open

  • Can ADM levels be used to time therapeutic intervention in sepsis?
  • Would ADM receptor antagonists help in late sepsis without harming early compensation?
  • Could monitoring ADM predict which sepsis patients will decompensate?

Common questions

Why does sepsis worsen suddenly?
The body's own vasodilator peptide adrenomedullin initially helps by maintaining blood flow. But as sepsis worsens, the lungs can't clear ADM fast enough, it accumulates, and blood pressure collapses — the same peptide becomes lethal.
Can this be treated?
ADM-targeting drugs (like adrecizumab) are being tested for sepsis. The key is timing — intervening before ADM accumulation causes irreversible cardiovascular collapse.

Read the original research

The role of adrenomedullin in producing differential hemodynamic responses during sepsis.

The Journal of surgical research, 95(2), 207-18

Citation

Koo, D J; Zhou, M; Chaudry, I H; Wang, P. (2001). The role of adrenomedullin in producing differential hemodynamic responses during sepsis.. The Journal of surgical research, 95(2), 207-18.